INTRODUCTION {#sec1-1}
============

Type 1 diabetes mellitus (T1DM) is a T-cell mediated, organ-specific autoimmune disorder leading to β-cell destruction and reduced insulin production and has no definitive cure currently. Standard treatment strategies for T1DM are based on different insulin replacements. However, as exogenous insulin cannot mimic exactly the physiology of insulin secretion, good metabolic control is difficult to reach and frequently associated with severe hypoglycemic episodes.\[[@ref1]\] At present, pancreas transplantation or islet transplantation as a treatment of T1DM is here to stay until something better comes along. The first efforts focused on whole pancreas transplants, which have been performed now for over 50 years. Although they have been shown to lead to insulin independence for several years, pancreas transplants to treat T1DM are not widespread for a number of reasons. Being a major surgery, the accompanying risk of mortality is 1-3% and the complications that ensue include cardiac death and systemic infections. In addition, to prevent the body from rejecting the transplanted pancreas, recipients must take powerful immunosupressions for the rest of their lives, leaving them susceptible to infections and a range of other diseases. Many feel that the immunosupressions therapy could be a greater health threat than the diabetes itself.\[[@ref2]\]

In an effort to more tightly control blood glucose levels, researchers began to explore the possibilities of using cell-based therapies that would replace lost β-cells. Within recent years, stem cell research has become a very important part of the scientific understanding of T1DM. Research has demonstrated that stem cells can be grown in the lab and could lead to a better availability of β-cells for future research purposes to treat T1DM. Many types of stem cells are candidates for the treatment of T1DM.\[[@ref3]\] The ideal stem cells would be the one with strong immunomodulatory and regenerative properties which would have to deal with active process of autoimmunity that probably target the newly formed insulin-producing cells (IPCs). Mesenchymal stem cells (MSCs) have been a driving force to initiate studies testing their therapeutic effectiveness with their regenerative capabilities and their immunomodulatory properties. Generation of IPCs from MSCs represents an attractive alternative.\[[@ref2]\] Although the sources of stem cells used in the generation of IPC have been previously reviewed, the literature describing MSCs alone as a source for *in vitro* transdifferentiation of IPC, further clinical use of IPC as a therapeutic agent in experimental animal models and in humans, and its outcome are limited, which encourage the author to carry out this review.

REVIEW {#sec1-2}
======

Mesenchymal stem cells therapeutic potential: *In vitro* and *in vivo* evidence {#sec2-1}
-------------------------------------------------------------------------------

Friedenstein *et al*., in a ground-breaking study, isolated clonogenic fibroblast precursor cells from whole bone marrow (BM) and showed that they were capable of forming bone- and cartilage-like colonies.\[[@ref4]\] Since then BM-derived stem cells are still the most frequently investigated cell type and often designated as the gold standard. Till date isolation of multipotent MSCs from different sources has been reported. There is no universally agreed upon set or a specific singular marker to identify these cells. As a result, a battery of negative and positive markers is generally used to phenotypically characterize these cells. As MSCs are a nonhematopoietic cell lineage, they generally lack specific cell surface markers of HSC and do not express hematopoietic markers such as CD34, CD14 and CD45, CD11a/LFA-1, erythrocytes (glycophorin A), and platelet and endothelial cell adhesion molecules (CD31), but they express several other cell surface antigens, such as CD73 (SH3/4), CD90, CD105 (SH2), CD146, and CD200. They also express variable levels of CD44, stromal antigen 1, and a group of other adhesion molecules and receptors including CD166 (vascular cell adhesion molecule), CD54/CD102 (intracellular adhesion molecule), and CD49.\[[@ref5]\] BM aspirate is considered to be the most accessible and enriched source of MSCs. Bone marrow-derived MSCs (BM-MSCs) represent a rare population of cells that make up only 0.001-0.01% of total nucleated cells and are 10-fold less abundant than hematopoietic stem cells (HSCs), but they can be readily grown and expanded in culture.\[[@ref6]\] However, MSCs derived from adipose tissue (AD-MSCs),\[[@ref7][@ref8]\] peripheral blood,\[[@ref9][@ref10]\] and umbilical cord blood (UCB)\[[@ref11][@ref12][@ref13]\] have also shown promising potential for proliferation and differentiation into different cell types including IPCs. Moreover, protein transduction technology also offers a novel approach for generating IPCs from stem cells including MSCs.\[[@ref14][@ref15]\]

Why MSC? {#sec2-2}
--------

The frequency of T1DM has been steadily increasing worldwide and T1DM prevention studies using immunosuppressants, self-antigens, and dietary interventions have demonstrated largely disappointing results.\[[@ref1]\] In T1DM, selective and irreversible destruction of the insulin-secreting β-cells in the pancreatic islets of Langerhans occurs by an autoimmune attack. While insulin replacement remains the cornerstone treatment for T1DM, the transplantation of pancreatic islets of Langerhans provides a cure for this disorder and yet, islet transplantation is limited by the lack of donor pancreas. The challenge involves the development of safe and effective means affording the prevention or reversal of T1DM. MSCs have the capacity to differentiate into multiple mesodermal and nonmesodermal cell lineages including IPCs *in vitro*.\[[@ref2]\] MSCs that have been precommitted to one mesenchyme cell lineage can differentiate into other cell types in response to inductive extracellular cues by process known as transdifferentiation. These precommitted cells proliferate and are able to dedifferentiate into a primitive stem cell stage through genome reprogramming.\[[@ref3]\] On the one hand, MSCs have the potential to transdifferentiate into IPCs by genetic modification and/or defined culture conditions *in vitro*. On the other hand, MSCs are able to serve as a cellular vehicle for the expression of human insulin gene and has a promising role as therapeutic agents in the treatment, the complications of DM such as cardiac function and in treatment of diabetic cardiomyopathy, nephropathy, diabetic polyneuropathy, and wounds in diabetic patients.\[[@ref16][@ref17][@ref18][@ref19][@ref20][@ref21][@ref22]\] MSCs have generated marked interest and attention for their capacity to elicit tissue regeneration\[[@ref6][@ref23][@ref24][@ref25]\] and one of the most remarkable and least understood findings is the ability of MSC to migrate to sites of tissue injury.\[[@ref26][@ref27][@ref28][@ref29]\] Besides, MSCs also possess immunosuppressive effects by modulating the immune function of the major cell populations involved in alloantigen recognition and elimination\[[@ref30][@ref31][@ref32]\] and they have also shown promising results in the treatment of other autoimmune disorders (e.g., experimental autoimmune encephalomyelitis and rheumatoid arthritis).\[[@ref33][@ref34]\] Adult human MSCs express intermediate levels of major histocompatibility complex (MHC) class I molecules on their cell surface, but not MHC class II, properties that allow their transplantation across MHC barriers. Because of the lack in expression of MHC class II and most of the classical costimulatory molecules on MSCs, these cells have historically been regarded as hypoimmunogenic cells. The immunomodulatory properties of MSCs were initially reported in T-cell proliferation assays using one of a variety of stimuli including mitogens, CD3/CD28, and alloantigen settings where the ability of MSCs to suppress T-cell proliferation was readily determined. Such suppression occurs irrespective of a donor source, including settings in which one uses "third-party" MSCs and suppress proliferation of both CD4+ and CD8+ lymphocytes; and are able to abrogate the response of memory T-cells and naïve T cells to their antigen.\[[@ref35]\] MSCs could regulate diabetes through a direct effect by presenting differential levels of negative costimulatory molecules and secreting regulatory cytokines such as transforming growth factor-β and IL-10 that control regulatory T-cells/auto-reactive T-cells. It is also possible that MSCs could correct the dysregulation observed at the level of B-cells and natural killer cells as well.\[[@ref36][@ref37][@ref38][@ref39]\] MSCs also exert antiinflammatory effects that could be important in maintaining peripheral tolerance.\[[@ref40][@ref41][@ref42]\] It has been shown that AD-MSCs are capable of producing anti-inflammatory cytokines and angiogenic factors, which could potentially improve the diabetes-associated inflammatory and ischemic conditions.\[[@ref2]\] According to one hypothesis, MSC transplantation into diabetic animals can prevent apoptosis of injured pancreatic β-cells and enhance regeneration of endogenous progenitor cells through paracrine actions such as angiogenic, cytoprotective, anti-inflammatory, mitogenic, and antiapoptotic effects.\[[@ref43]\] MSCs have been also shown to provide cytokine and growth factor support for expansion of HSCs and human embryonic stem cells (ESCs), which in turn during cotransplantation of IPCs and HSCs promote IPC engraftment and survival. Here HSCs act as "feeder" cells for the IPCs, supporting its protection, tissue revascularization, and immune acceptance.\[[@ref25][@ref44][@ref45][@ref46]\]

*In vitro* directed transdifferentiation of mscs into IPCs {#sec2-3}
----------------------------------------------------------

Assady *et al*. (2001) reported that IPCs can be generated from spontaneous differentiation using ESCs. Although the number of IPCs and the insulin content in these cells was low, it was the first proof-of-principle experiment showing that stem cells-ESCs were a potential source for generating β-like cells.\[[@ref47]\]

MSCs have the advantage over ESCs in that they usually do not form teratomas and are free from the ethical issues of ESCs. MSCs can be easily obtained and are easily expanded and cultured in the laboratory. Different types of stem cells require different culture and induction media for transdifferentiation of IPCs to take place. The capacity of MSCs to undergo functional transdifferentiation has been questioned over the years. Nonetheless, recent studies support that gene-therapy or factor-based transdifferentiation of MSCs are two distinctive pathways to be considered as means of obtaining functional β-cells. Gene-therapy refers to the *in vivo* or *in vitro* transfer of a foreign gene into MSCs, allowing it to produce insulin. The foreign gene in turn activates or represses on demand the insulin gene. The factor-based approach involves exposing MSCs to a cocktail of insulin-promoting factors and cytokines over an extended period of *in vitro* culture, followed by transplantation of the transdifferentiated IPC into the receiving diabetic patient.

MSCs can be differentiated into IPCs by using a specific culture medium enriched with extrinsic insulin-promoting factors. The IPC transdifferentiation period varies greatly with the use of different protocols, it may last from several days to several months. Addition and withdrawal of a combination of extrinsic insulin-promoting factors in a stage-wise manner are required. Many extrinsic insulin-promoting factors, which are biologically active compounds, that have been used in endocrine pancreas differentiation have been shown to promote β-cell proliferation and differentiation and increase insulin content of IPC. A number of these factors have been commonly observed in protocols for IPC transdifferentiation. Different types of stem cells require different culture and induction media for differentiation of IPCs to take place. However, some common themes seem to appear in various induction methods. Commonly known insulin-promoting factors include epidermal growth factor, activin A, betacellulin, nicotinamide, exendin-4, hepatocyte growth factor, fibroblast growth factors, and pentagastrin. Careful use of serum and glucose in the induction media has also been indicated for successful transdifferentiation of IPCs. Signaling by these factors in MSCs allows the induction of the transcription factors, which are prerequisites for pancreas development \[[Table 1](#T1){ref-type="table"}\].

###### 

Extrinsic factors and their role in promoting IPC differentiation and insulin production

![](ABR-3-266-g001)

IPC identification is then based on the ability to express genes related to pancreatic development and function, such as *IslI* and *IslII*, *GLUT2*, glucose kinase, islet amyloid polypeptide, nestin, and *Pdx 1* and *Pax 6*, and to synthesize C-peptide and insulin, which have been shown to play a role in the development of the pancreas and/or the differentiation of insulin-producing β-cells. Although pancreas development has been partly deciphered by identification and characterization of many transcription factors little is known about their function and molecular mechanism of action. Most of these transcription factors are sequentially and transiently expressed during pancreas development. However, for successful transdifferentiation of MSCs into IPCs the *in vitro* culture procedure should follow at least the major part of transcriptional program.

There are evidence to suggest that pancreatic stem or progenitor cells derived MSCs.\[[@ref48][@ref49][@ref50][@ref51][@ref52][@ref53][@ref54]\] UCB derived MSCs,\[[@ref13][@ref55][@ref56]\] BM-MSCs,\[[@ref57][@ref58][@ref59][@ref60][@ref61][@ref62][@ref63]\] and AD-MSC\[[@ref52][@ref64][@ref65][@ref66]\] can be isolated from rodents and/or human and extensively expanded *in vitro*, where they differentiate to form new IPCs and exhibited with the characteristics genes and a panel of markers considered essential for differentiation into pancreatic endocrine tissue (*Isl1*, *Pdx 1*, *Pax 4*, and *Ngn3*, *Pax 6*) \[[Table 2](#T2){ref-type="table"}\].

###### 

*In vitro* approaches to generate IPCs from different MSC sources

![](ABR-3-266-g002)

The majority of researchers have described a multistep protocol for generation of insulin-producing islet-like clusters from MSCs derived from different sources. The glucose challenge tests revealed the production of insulin, and such production was regulated through physiological signaling pathways, i.e. in a glucose responsible manner and they believed that IPCs derived from MSCs could be potentially used for cell therapy of T1DM in human models followed by trials in experimental animal models \[[Figure 1](#F1){ref-type="fig"}\].

![Schematic representation showing *in vitro* transdifferentiation of insulin-producing cells from mesenchymal stem cells; IPC *in vivo* infusion in an experimental animal model, T1DM human model, and therapeutic effect](ABR-3-266-g003){#F1}

Success story: MSCs derived IPCs-based therapy in autoimmune animal models of T1DM {#sec2-4}
----------------------------------------------------------------------------------

Experimental data for the therapeutic effects of MSCs-derived IPCs in animal models of T1DM are important tools for analyzing results before considering further human clinical applications. NOD/SCID mice, which are severely deficient in T and B lymphocytes, represent an invaluable diabetic model for experimental research. Use of IPCs derived from UCB-MSCs,\[[@ref56][@ref67][@ref68]\] BM-MSCs alone or in association with HSCs,\[[@ref18][@ref59][@ref69][@ref70][@ref71]\] and from AD-MSC\[[@ref72][@ref73][@ref74][@ref75]\] represent a potential source of diabetic cell replacement. AD-MSCs because of their availability, low risk for immune rejection and increased capacity for expansion with encouraging results in terms of improving glycaemia, enhanced islet regeneration, lowered blood sugar and increased circulating blood insulin levels, increased production of endogenous β-cells, reversion of glycosuria, with increased morphologically normal β-pancreatic islets, acquired functional β-cell phenotype, partially restored pancreatic function in comparison with nontransplanted diabetic mice. Histological examination of IPCs transplanted organ showed the presence of transplanted cells with formation of tissue-like structure, which stained positive for insulin [Table 3](#T3){ref-type="table"}.

###### 

Approaches to treat experimental diabetic model using IPCs generated from different MSC sources
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MSCs or MSCs derived IPC-based therapy in T1DM humans {#sec2-5}
-----------------------------------------------------

The most effective protocols till date have produced cells that express insulin and have molecular characteristics that closely resemble bonafide IPC; however, these cells are often unresponsive to glucose, which is also a most vital characteristic concern that needs to be solved before finding a definite clinical application. There are very few reports noted till now using MSCs-derived IPC as a treatment of T1DM in humans. In 2008, researchers studied the role of MSCs in humans with T1DM. The protocol includes BM biopsy under general anesthesia in the first-degree relatives for the collection of MSC. These cells were sent to a laboratory to be stimulated to proliferate for a month and were later infused into the patient through a gelatinous solution of approximately 100 mL without chemotherapy. After 1 month, the patients were given another infusion. So far, they are not sure about how many infusions will be necessary. Two patients had been included in this protocol but still results are not published.\[[@ref76]\]

In the same year, in 2008, Trivedi *et al*. published results using AD-MSCs transdifferentiated IPCs in combination with HSCs to treat T1DM in five patients having disease duration of 0.6-10 years. Intraportal administration of *in vitro* generated IPCs and HSCs were carried out. We decided to infuse the cells in portal circulation since liver is the most tolerogenic organ.\[[@ref77]\] The results showed 30% to 50% decreased insulin requirements with 4 to 26-fold increased serum c-peptide levels, with a mean follow-up of 2.9 months without any untoward effects and without use of any immunosuppression.\[[@ref78]\]

In 2010, again vanikar *et al*. published results of insulin replacement therapy using AD-MSCs-derived IPC in combination with HSCs to treat T1DM in another 11 patients having disease duration of 1-24 years. Cells were administered intraportally. In vitro generated IPCs showed the presence of pancreatic transcriptional factors *Pax 6*, *Isl1*, and *Pdx 1* (by immunoflurescence assay). Chemiluminescence assay detected secretion of glucose and C-peptide in response to glucose concentration *in vitro*. Over a mean follow-up of 23 months, treated patients showed a decreased mean exogenous insulin requirement, Hb1Ac, raised serum c-peptide levels, and became free of diabetic ketoacidosis events with weight gain on normal diet and physical activities without any untoward effects, without use of any immunosuppression\[[@ref79]\] \[[Table 4](#T4){ref-type="table"}\].

###### 

Insulin replacement therapy using MSC-derived IPCs in humans
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CONCLUSIONS AND FUTURE PERSPECTIVES {#sec1-3}
===================================

Taken altogether, these *in vitro* and *in vivo* experiments demonstrate that the beneficial effects of MSCs in T1DM may be related to both their immunosuppressant activity and subsequent protective effects on damaged tissue, and their capacity to transdifferentiate into IPCs \[[Figure 2](#F2){ref-type="fig"}\].

![MSC transdifferentiation into IPC and its use in clinic learning points](ABR-3-266-g006){#F2}

With sporadic reports of use of MSCs-derived IPCs and their further use in clinical trials to treat T1DM, it can be concluded that (i) this study is only a first step toward using MSCs-derived IPCs as a cell-based treatment, which appears to be suitable for treatment of for T1DM, (ii) MSCs-derived IPCs are an ideal population of personal stem cells for cell replacement therapy and also MSCs could be induced to differentiate into physiologically competent functional islet-like cell aggregates, which may provide as a source of alternative islets for cell replacement therapy in T1DM. Generation of MSCs into IPCs is feasible and promising making the transplantation of IPC a promising approach for the treatment of T1DM. However, there is no standard method for IPC generation and the wide variations in induction techniques used may be a challenge to researchers. As most of these stem cells are being tested in preclinical T1DM with rare clinical use in humans, further exploration is necessary for the *in vitro* generation of sufficient IPCs that can produce sufficient insulin for wide clinical use. The biggest challenge for the future trials using this approach is to prevent or treat relapses and maintain complete or very good partial responses for very long time.

**Source of Support:** Nil

**Conflict of Interest:** None declared
